HOOKIPA Pharma reported Q3 2024 financial results with a net loss of $13.8M, compared to $19.1M in Q3 2023. Revenue decreased to $4.7M from $6.9M YoY due to lower partnering revenues. The company ended Q3 with $60M in cash, down from $117.5M at 2023 year-end.The company achieved significant clinical milestones, completing enrollment of 68 patients in Phase 2 study of eseba-vec plus pembrolizumab for HPV16+ head and neck cancer ahead of schedule. First patients were dosed in a new Phase 2 adjuvant therapy trial at Memorial Sloan Kettering Cancer Center. Additionally, HOOKIPA received a $5M milestone payment from Gilead for initiating HB-500 HIV trial.Operating expenses decreased with R&D costs at $15.6M versus $24.6M YoY, while G&A expenses increased to $6.7M from $4.9M. The company implemented cost optimization initiatives and underwent management changes, including appointing Malte Peters as CEO and Terry Coelho as CFO in July 2024.

HOOKIPA Pharma reported Q3 2024 financial results with a net loss of $13.8M, compared to $19.1M in Q3 2023. Revenue decreased to $4.7M from $6.9M YoY due to lower partnering revenues. The company ended Q3 with $60M in cash, down from $117.5M at 2023 year-end.The company achieved significant clinical milestones, completing enrollment of 68 patients in Phase 2 study of eseba-vec plus pembrolizumab for HPV16+ head and neck cancer ahead of schedule. First patients were dosed in a new Phase 2 adjuvant therapy trial at Memorial Sloan Kettering Cancer Center. Additionally, HOOKIPA received a $5M milestone payment from Gilead for initiating HB-500 HIV trial.Operating expenses decreased with R&D costs at $15.6M versus $24.6M YoY, while G&A expenses increased to $6.7M from $4.9M. The company implemented cost optimization initiatives and underwent management changes, including appointing Malte Peters as CEO and Terry Coelho as CFO in July 2024.